Evidence map›Paper›PMID 32277281›Full record

SynthesisSurgery today2021

Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.

Motoi Uchino, Hiroki Ikeuchi, Junzo Shimizu, Hiroki Ohge, Seiji Haji, Toru Mizuguchi, Yasuhiko Mohri, Chizuru Yamashita, Yuichi Kitagawa, Katsunori Suzuki and 7 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Surgery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Biologics and infections: understand and recognize].Dermatologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Motoi UchinoDepartment of Inflammatory Bowel Disease, Hyogo College of Medicine, 1-1, Mukogawacho, Nishinomiya, Hyogo, Japan. uchino2s@hyo-med.ac.jp.
Hiroki IkeuchiDepartment of Inflammatory Bowel Disease, Hyogo College of Medicine, 1-1, Mukogawacho, Nishinomiya, Hyogo, Japan.
Junzo ShimizuDepartment of Surgery, Toyonaka Municipal Hospital, Osaka, Japan.
Hiroki OhgeDepartment of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
Seiji HajiDepartment of Surgery, Takatsuki General Hospital, Osaka, Japan.
Toru MizuguchiDepartment of Nursing, Surgical Science and Technology, Sapporo Medical University, Sapporo, Japan.
Yasuhiko MohriDepartment of Surgery, Mie Prefectural General Medical Center, Mie, Japan.
Chizuru YamashitaDepartment of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Aichi, Japan.
Yuichi KitagawaDepartment of Infection Control, National Center for Geriatrics and Gerontology, Aichi, Japan.
Katsunori SuzukiDivision of Infection Control and Prevention, University of Occupational and Environmental Health, Fukuoka, Japan.
Motomu KobayashiDepartment of Anesthesiology and Resuscitology, Okayama University Hospital, Okayama, Japan.
Masahiro KobayashiKitasato University School of Pharmacy, Tokyo, Japan.
Fumie SakamotoInfection Control Manager, QI Center, St. Luke's International Hospital, Tokyo, Japan.
Masahiro YoshidaHemodialysis and Surgery, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.
Toshihiko MayumiDepartment of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Koichi HirataDepartment of Surgery, JR Sapporo Hospital, Sapporo, Japan.
Yoshio TakesueDivision of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan.
Hyogo Medical University · JPUniversity of Occupational and Environmental Health Japan · JPFujita Health University · JPHiroshima University Hospital · JPInternational University of Health and Welfare · JPKeiyukai Sapporo Hospital · JPKitasato University · JPNational Center for Geriatrics and Gerontology · JPOkayama University Hospital · JPSapporo Medical University · JPSt. Luke's International Hospital · JPTakatsuki General Hospital · JPToyonaka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor-alpha inhibitor (TNFi) treatment is effective for ulcerative colitis (UC) and Crohn's disease (CD). Although several meta-analyses have been performed to evaluate the association between TNFi treatment and surgical morbidity, the results are controversial. We conducted a systematic review and meta-analysis of the prevention of surgical site infection (SSI) after surgery for UC and CD in patients on TNFis, based on literature published between January 2000 and May 2019 (registered on PROSPERO, No. CRD42019134156). Overall, 2175 UC patients in 13 observational studies (OBSs) and 7084 CD patients in 16 OBSs were included. The incidences of incisional (INC) SSI and organ/space (O/S) SSI after surgery for UC were 179/1985 (9.0%) and 176/2175 (8.1%), respectively. TNFi use was not associated with the incidences of INC SSI (odds ratio (OR) 1.04, 95% confidence interval (CI) (0.47-2.32) or O/S SSI (OR 1.85, 95% CI (0.82-4.20)) after surgery for UC. The INC SSI and O/S SSI incidences after surgery for CD were 289/3089 (9.4%) and 526/7,084 (7.4%), respectively. Preoperative TNFi use was not associated with INC SSI (OR 0.98, 95% CI (0.52-1.83)) or O/S SSI incidence (OR 1.09, 95% CI (0.78-1.52)) after surgery for CD. We did not find a significant association between preoperative TNFi use and SSI in surgery for UC or CD.

Indexed as

Colitis, UlcerativeCrohn DiseaseDigestive System Surgical ProceduresHumansIncidencePreoperative CareSurgical Wound InfectionTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaCrohn’s diseasePostoperative complicationsSurgical site infectionTumor necrosis factor alpha inhibitorUlcerative colitis

Identifiers

PMID32277281
OpenAlexW3015344666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.